TC
UTHR icon

TFS Capital’s United Therapeutics UTHR Stock Holding History

TFS Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,489
Closed -$453K – 344
2017
Q2 		$453K Buy
+3,489
New +$435K 0.18% 196
2013
Q3 		– Sell
-235,109
Closed -$15.5M – 1637
2013
Q2 		$15.5M Buy
+235,109
New +$15.1M 0.65% 6

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

TFS Capital's UTHR Position: Q3 2017 in Review

TFS Capital sold out of United Therapeutics (UTHR) in Q3 2017, closing a stake of 3,489 shares — an estimated $453K sold.

TFS Capital first reported a position in UTHR in Q2 2013 and held it in 2 quarters. The position peaked at $15.5M in Q2 2013. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2017.

  • TFS Capital reported no remaining United Therapeutics position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 3,489 United Therapeutics shares in Q3 2017, an estimated $453K.
  • TFS Capital first reported a position in United Therapeutics in Q2 2013 and held it in 2 quarters.
  • TFS Capital's United Therapeutics position peaked at $15.5M in Q2 2013.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.